Windtree Therapeutics Inc Stock Price, News & Analysis

Windtree Therapeutics (WINT) reported second-quarter results for 2021, highlighting ongoing clinical trials for istaroxime and lucinactant, targeting cardiogenic shock and COVID-19 lung injury respectively. The operating loss reached $45.4 million, largely due to a $37.8 million impairment on rostafuroxin assets. R&D expenses decreased to $4.2 million, and general administrative costs were stable at $3.4 million. A net loss of $37.4 million ($1.42 per share) was recorded. The company maintains a cash position of $30 million, expected to support operations for at least the next year.

Windtree Therapeutics (NasdaqCM: WINT) has appointed Randall White, Ph.D., as Vice President of Clinical Program Management. Dr. White brings over 20 years of pharmaceutical research experience, previously serving at Daiichi Sankyo and Bristol-Myers Squibb. His expertise will support Windtree's clinical development projects. To incentivize his employment, the company granted Dr. White a stock option for 100,000 shares at the closing price on the grant date. Windtree focuses on interventions for acute cardiovascular and pulmonary disorders, with key products including istaroxime and AEROSURF®.

Windtree Therapeutics, focused on acute cardiovascular and pulmonary therapies, announced CEO Craig Fraser's upcoming presentation at the Access to Giving Virtual Investor conference from July 13-15, 2021. Windtree is scheduled to present on July 15, 2021, at 10:00 AM ET. The conference will feature over 50 companies and aims to promote investor education and advocacy, with funds raised directed to financial literacy initiatives. The presentation will be available for replay on the company’s website, and one-on-one meetings can be arranged with management.

Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 11:00 am ET. The presentation will cover the company's innovative therapies for acute cardiovascular and pulmonary disorders. Windtree is developing istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A replay will be available on their investor page.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the appointment of Diane Carman as Senior Vice President and General Counsel, effective July 1, 2021. Ms. Carman, with over 20 years of experience in the biotech sector, has a proven track record in legal compliance, corporate governance, and M&A. She previously served as General Counsel for various companies, including Vitara Biomedical. Her appointment is expected to bolster Windtree's legal framework as it advances late-stage interventions for acute cardiovascular and pulmonary disorders. Ms. Carman received stock options to purchase 150,000 shares as part of her inducement to join the company.

Windtree Therapeutics (WINT) reported Q1 2021 results, highlighting an operating loss of $9.1 million, up from $6.7 million in Q1 2020. Research and development expenses increased to $4.4 million, driven by clinical development for istaroxime. The company raised approximately $30 million in equity financing, netting $27.4 million. Key updates include expanding a Phase 2 clinical study for istaroxime and dosing the first patient in a study of lucinactant for COVID-19 related acute lung injury. Cash and equivalents stood at $38.5 million as of March 31, 2021.

Windtree Therapeutics (NasdaqCM: WINT) announced the filing of a Track One prioritized patent application with the USPTO for istaroxime. This expedited process is expected to yield examination results within one year, compared to the usual three years. Istaroxime, the company's lead asset, is under development for early cardiogenic shock and acute heart failure (AHF). The company is conducting an international study involving 60 patients to evaluate istaroxime's efficacy. Following positive phase 2 trials, Windtree plans further phase 2b trials to optimize therapy for specific patient populations.

Windtree Therapeutics reported a net loss of $32.6 million for 2020, with an operating loss of $30.3 million. In Q4 2020, the company had a net loss of $7.5 million, reflecting increased expenses in R&D and G&A. The company completed a $30 million equity financing in Q1 2021, netting approximately $27.3 million to fund ongoing clinical trials for istaroxime and KL4 surfactant. The company also announced a new patent for its AEROSURF device, extending protection until 2039. Cash and equivalents stood at $16.9 million at year-end 2020.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has closed a public offering of 9,230,500 shares of common stock at $3.25 per share, generating gross proceeds of approximately $30 million. The offering included warrants to purchase an equal number of shares at an exercise price of $3.60. Proceeds will fund the advancement of the lead product istaroxime for acute heart failure and continue developing other pipeline candidates. Oppenheimer & Co. and Ladenburg Thalmann acted as managers for the offering, which was conducted under a previously effective shelf registration statement.